For: | Wang GY, Zhang XY, Wang CJ, Guan YF. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies. World J Gastroenterol 2023; 29(1): 75-95 [PMID: PMC9850950 DOI: 10.3748/wjg.v29.i1.75] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i1/75.htm |
Number | Citing Articles |
1 |
Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía. Metabolic Dysfunction-Associated Steatotic Liver Disease. 2024; : 115 doi: 10.1007/978-981-97-9519-2_10
|
2 |
Fenfen Li, Ruyan Yuan, Jiamin Zhang, Bing Su, Xiaolong Qi. Advances in Nanotechnology for the Diagnosis and Management of Metabolic Dysfunction-associated Steatotic Liver Disease. Asian Journal of Pharmaceutical Sciences 2025; : 101025 doi: 10.1016/j.ajps.2025.101025
|
3 |
Yongyi Liang, Shaojun Qiu, Youwen Zou, Lianxiang Luo. Targeting ferroptosis with natural products in liver injury: new insights from molecular mechanisms to targeted therapies. Phytomedicine 2024; 122: 155134 doi: 10.1016/j.phymed.2023.155134
|
4 |
Zhichao Lang, Suhui Yu, Yuhang Hu, Qiqi Tao, Jingnan Zhang, Haoyue Wang, Lei Zheng, Zhixian Yu, Jianjian Zheng. Ginsenoside Rh2 promotes hepatic stellate cell ferroptosis and inactivation via regulation of IRF1-inhibited SLC7A11. Phytomedicine 2023; 118: 154950 doi: 10.1016/j.phymed.2023.154950
|
5 |
Lucia Longhitano, Alfio Distefano, Nicolò Musso, Paolo Bonacci, Laura Orlando, Sebastiano Giallongo, Daniele Tibullo, Simona Denaro, Giuseppe Lazzarino, Jessica Ferrigno, Anna Nicolosi, Amer M. Alanazi, Federico Salomone, Emanuela Tropea, Ignazio Alberto Barbagallo, Vincenzo Bramanti, Giovanni Li Volti, Giacomo Lazzarino, Daniele Torella, Angela Maria Amorini. (+)-Lipoic acid reduces mitochondrial unfolded protein response and attenuates oxidative stress and aging in an in vitro model of non-alcoholic fatty liver disease. Journal of Translational Medicine 2024; 22(1) doi: 10.1186/s12967-024-04880-x
|